Anne-Laure Grillot,Cornelia J. Forster,David J. Lauffer,Guy W. Bemis,James W. Janetka,Keith P. Wilson,Marion W. Wannamaker,Mark A. Murcko,Michael D. Mullican,Paul S. Charifson,Robert J. Davies,Zhan Sh
申请号：
BRPI9917881
公开号：
BRPI9917881B1
申请日:
1999.03.19
申请国别(地区):
BR
年份:
2018
代理人:
摘要：
Inhibitors of caspases, pharmaceutical composition and use of said compounds.The present invention relates to new classes of compounds that are inhibitors of caspase, particularly inhibitors of converting enzyme of interleukin-1 beta (\"ice\").The invention also relates to pharmaceutical compositions comprising these compounds.The compounds and pharmaceutical compositions of this invention are particularly well suited for the inhibition of caspase activity and, consequently,Can be advantageously used as agents against diseases mediated by interleukin-1 (IL-1), apoptosis induction factor of interferon - sym ((GIF), or interferon - (IFN - sym sym \").Including inflammatory diseases, autoimmune diseases, disorders of the bone destructive, proliferative disorders, infectious diseases, and degenerative diseases.The invention also relates to methods for the inhibition of caspase activity and decreased production of IGIF and production of IFN - sym and to methods for the treatment of diseases mediated by interfeRon - sym, apoptosis, and interleukin - 1 by using the compounds and compositions of this invention. The invention also relates to methods for the preparation of the compounds of this invention.compostos inibidores de caspases, composição farmacêutica e uso de ditos compostos. a presente invenção refere-se a novas classes de compostos que são inibidores de caspase, em particular inibidores de enzima de conversão de interleucina-1 beta ("ice"). esta invenção também refere-se a composições farmacêuticas compreendendo estes compostos. os compostos e as composições farmacêuticas desta invenção são particularmente bem adequados para a inibição de atividade de caspase e consequentemente, podem ser vantajosamente usados como agentes contra doenças mediadas por interleucina-1 ("il-1"), apoptose, fator de indução de interferon- (i-gif), ou interferon- ("ifn-"), incluindo doenças inflamatórias, doenças auto-imunes, distúrbios de osso destrutivos, distú
